Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mehrzad Zarghouni

Vascular & Interventional Radiology Bellaire, TX Medical Doctor

NPI 1780900993 CMS profile 1182738

6565 West Loop S Ste 110, Bellaire, TX 77401

Open in the dashboard

General payments

$127,221

161 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mehrzad Zarghouni of Bellaire, TX is reported in the CMS Open Payments database as having received $127,221 across 161 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $29,373 45
2024 General $46,081 43
2023 General $36,546 29
2022 General $14,200 23
2021 General $428 8
2020 General $288 7
2019 General $304 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mehrzad Zarghouni
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Mehrzad Zarghouni were reported at $29,373. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Mehrzad Zarghouni Vascular & Interventional Radiology median Middle half National median
2019 $304 $422 $125–$1,555 $163
2020 $288 $200 $68–$652 $114
2021 $428 $280 $99–$866 $132
2022 $14,200 $433 $137–$1,497 $149
2023 $36,546 $506 $152–$2,019 $160
2024 $46,081 $556 $175–$1,930 $164
2025 $29,373 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $115,529 69 payments
  2. Cardiovascular Systems Inc. $6,974 13 payments
  3. Endologix, Inc. $2,771 14 payments
  4. Bard Peripheral Vascular, Inc. $430 10 payments
  5. Medtronic, Inc. $231 8 payments
  6. Philips Electronics North America Corporation $180 3 payments
  7. Ablative Solutions, Inc. $108 1 payment
  8. ETS Wound Care LLC $88 3 payments
  9. Tactile Systems Technology Inc $87 5 payments
  10. Stryker Corporation $75 2 payments
  11. Other $747 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $114,082 7 payments
  2. Food and Beverage $6,840 152 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $6,300 2 payments
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac Et $87,278 6 payments
  2. Auryon Laser System 100-120 Vac Cv $24,250 1 payment
  3. Diamondback Peripheral $3,931 9 payments
  4. Diamondback Coronary $2,880 1 payment
  5. Torus Stent Graft System $2,771 14 payments
  6. VenaCure 1470 Pro $2,707 1 payment
  7. ENDOCROSS Device $2,411 12 payments
  8. AURYON LASER SYSTEM 100-120 VAC Pad $1,228 60 payments
  9. Peripheral Orbital Atherectomy System $163 3 payments
  10. (6577) Visions 014 $102 1 payment
  11. Other $1,730 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

454

Median for Diagnostic Radiology: 24

Drug cost

$184,199

Median for Diagnostic Radiology: $190

Branded share of claims

68.3%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 202 $171,284
Eliquis Apixaban Brand 13 $10,548
Cilostazol Generic 24 $448
Pregabalin Generic 22 $431
Gabapentin Generic 16 $384
Clopidogrel Clopidogrel Bisulfate Brand 40 $341
Acetaminophen-Codeine Acetaminophen With Codeine Brand 36 $239
Atorvastatin Calcium Generic 16 $167
Tramadol Hcl Generic 36 $143
Ibuprofen Generic 30 $134

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 119 billing codes

Paid by Medicare

$945,376

Of which drugs: $545

Medicare patients

187

Average age 75

Services billed

6,794

118 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 48%
Chronic kidney disease 43%
Ischemic heart disease 42%
Heart failure 29%
Osteoporosis 24%
Atrial fibrillation 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 41 4,559 $469

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

161 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record